Smarter Oncology Management Needed as Costs Continue to Climb

Why It Matters

Rising oncology expenses threaten plan sustainability; smarter management can protect margins without compromising patient outcomes.

Key Takeaways

• Oncology drugs now represent 50‑60% of health‑plan cancer spend.
• Soft‑steering programs identify lower‑cost equivalents without denying therapy.
• Hard steering redirects infusions to home or office settings for savings.
• Multidisciplinary utilization teams cut denials and improve value‑based decisions.
• Value‑based specialty care could save $50‑60 billion annually.

Pulse Analysis

The surge in oncology spending is reshaping payer strategies across the United States. As more therapies receive FDA approval and treatment durations extend, cancer drugs now dominate health‑plan budgets, often straddling both medical and pharmacy benefits. This dual‑benefit exposure creates fragmented review processes, leading to duplicated toxicities and inflated total cost of care. Payers are therefore compelled to move beyond drug‑by‑drug scrutiny toward holistic, cross‑benefit utilization models that assess entire treatment protocols and align them with evidence‑based outcomes.

Two practical levers are gaining traction: soft steering and hard steering. Soft steering leverages pharmacists and actuarial analytics to surface clinically equivalent, lower‑net‑cost alternatives—such as generics, biosimilars, or dose‑optimization strategies—while preserving prescriber autonomy and avoiding outright denials. Hard steering, by contrast, mandates site‑of‑care shifts, moving appropriate infusions from high‑cost hospital outpatient settings to home infusion or physician offices. Both approaches rely on multidisciplinary teams that include oncologists, certified oncology nurses, and board‑certified oncology pharmacists, which have been shown to reduce claim denials, streamline appeals, and improve overall value perception.

The broader vision is a transition to value‑based specialty care, a model McKinsey estimates could save $50‑60 billion annually. Realizing this potential demands robust data sharing, trust among stakeholders, and flexible contracts that reward outcomes over volume. While operational complexity and regional variability pose challenges, early adopters that integrate soft‑steering analytics with hard‑steering site‑of‑care programs are already reporting measurable savings and higher member satisfaction. As oncology therapies continue to evolve, payers that embed these smarter management frameworks will be better positioned to sustain financial health while delivering high‑quality cancer care.